MOH vs. MRNA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at MOH and MRNA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | MOH | MRNA |
|---|---|---|
| Company Name | Molina Healthcare, Inc. | Moderna, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Providers & Services | Biotechnology |
| Market Capitalization | 7.59 billion USD | 9.70 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | July 2, 2003 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of MOH and MRNA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | MOH | MRNA |
|---|---|---|
| 5-Day Price Return | -2.38% | 0.04% |
| 13-Week Price Return | -17.88% | -11.60% |
| 26-Week Price Return | -55.70% | -2.82% |
| 52-Week Price Return | -55.53% | -41.22% |
| Month-to-Date Return | -10.14% | -8.80% |
| Year-to-Date Return | -52.74% | -40.43% |
| 10-Day Avg. Volume | 1.74M | 11.56M |
| 3-Month Avg. Volume | 1.67M | 10.45M |
| 3-Month Volatility | 52.05% | 59.86% |
| Beta | 0.51 | 1.20 |
Profitability
Return on Equity (TTM)
MOH
20.07%
Health Care Providers & Services Industry
- Max
- 24.67%
- Q3
- 15.54%
- Median
- 8.37%
- Q1
- 5.49%
- Min
- -2.09%
In the upper quartile for the Health Care Providers & Services industry, MOH’s Return on Equity of 20.07% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
MRNA
-31.40%
Biotechnology Industry
- Max
- 96.19%
- Q3
- 12.45%
- Median
- -16.39%
- Q1
- -47.43%
- Min
- -131.19%
MRNA has a negative Return on Equity of -31.40%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
MOH
1.98%
Health Care Providers & Services Industry
- Max
- 9.33%
- Q3
- 4.80%
- Median
- 2.90%
- Q1
- 0.93%
- Min
- -3.28%
MOH’s Net Profit Margin of 1.98% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
MRNA
-139.61%
Biotechnology Industry
- Max
- 84.13%
- Q3
- 19.34%
- Median
- -1.39%
- Q1
- -117.64%
- Min
- -296.77%
MRNA has a negative Net Profit Margin of -139.61%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
MOH
2.97%
Health Care Providers & Services Industry
- Max
- 18.35%
- Q3
- 8.71%
- Median
- 5.10%
- Q1
- 2.10%
- Min
- -3.07%
MOH’s Operating Profit Margin of 2.97% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
MRNA
-155.15%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 20.86%
- Median
- 0.51%
- Q1
- -128.29%
- Min
- -315.84%
MRNA has a negative Operating Profit Margin of -155.15%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | MOH | MRNA |
|---|---|---|
| Return on Equity (TTM) | 20.07% | -31.40% |
| Return on Assets (TTM) | 5.53% | -24.44% |
| Net Profit Margin (TTM) | 1.98% | -139.61% |
| Operating Profit Margin (TTM) | 2.97% | -155.15% |
| Gross Profit Margin (TTM) | 13.91% | 63.49% |
Financial Strength
Current Ratio (MRQ)
MOH
1.68
Health Care Providers & Services Industry
- Max
- 2.00
- Q3
- 1.56
- Median
- 1.28
- Q1
- 0.92
- Min
- 0.01
MOH’s Current Ratio of 1.68 is in the upper quartile for the Health Care Providers & Services industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.
MRNA
3.93
Biotechnology Industry
- Max
- 15.83
- Q3
- 7.97
- Median
- 4.06
- Q1
- 2.64
- Min
- 0.72
MRNA’s Current Ratio of 3.93 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
MOH
0.92
Health Care Providers & Services Industry
- Max
- 2.41
- Q3
- 1.39
- Median
- 0.74
- Q1
- 0.46
- Min
- 0.00
MOH’s Debt-to-Equity Ratio of 0.92 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
MRNA
0.01
Biotechnology Industry
- Max
- 1.27
- Q3
- 0.62
- Median
- 0.13
- Q1
- 0.00
- Min
- 0.00
MRNA’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
MOH
14.47
Health Care Providers & Services Industry
- Max
- 14.47
- Q3
- 7.46
- Median
- 4.52
- Q1
- 2.04
- Min
- -4.44
MOH’s Interest Coverage Ratio of 14.47 is in the upper quartile for the Health Care Providers & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
MRNA
--
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.71
- Median
- -15.18
- Q1
- -65.75
- Min
- -166.46
Interest Coverage Ratio data for MRNA is currently unavailable.
Financial Strength at a Glance
| Symbol | MOH | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.68 | 3.93 |
| Quick Ratio (MRQ) | 1.60 | 3.40 |
| Debt-to-Equity Ratio (MRQ) | 0.92 | 0.01 |
| Interest Coverage Ratio (TTM) | 14.47 | -- |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 5.51%
- Q3
- 2.66%
- Median
- 1.06%
- Q1
- 0.00%
- Min
- 0.00%
MOH currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
MOH
0.00%
Health Care Providers & Services Industry
- Max
- 187.56%
- Q3
- 81.14%
- Median
- 33.42%
- Q1
- 0.00%
- Min
- 0.00%
MOH has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
MRNA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | MOH | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
MOH
8.01
Health Care Providers & Services Industry
- Max
- 48.86
- Q3
- 32.22
- Median
- 21.78
- Q1
- 13.97
- Min
- 8.01
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/E Ratio of 8.01 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
MRNA
--
Biotechnology Industry
- Max
- 115.91
- Q3
- 56.76
- Median
- 21.80
- Q1
- 15.79
- Min
- 4.51
P/E Ratio data for MRNA is currently unavailable.
Price-to-Sales Ratio (TTM)
MOH
0.16
Health Care Providers & Services Industry
- Max
- 3.66
- Q3
- 1.64
- Median
- 0.72
- Q1
- 0.27
- Min
- 0.10
In the lower quartile for the Health Care Providers & Services industry, MOH’s P/S Ratio of 0.16 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
MRNA
4.30
Biotechnology Industry
- Max
- 58.56
- Q3
- 29.31
- Median
- 8.30
- Q1
- 4.89
- Min
- 0.86
In the lower quartile for the Biotechnology industry, MRNA’s P/S Ratio of 4.30 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
MOH
2.47
Health Care Providers & Services Industry
- Max
- 7.33
- Q3
- 4.33
- Median
- 2.48
- Q1
- 1.31
- Min
- 0.65
MOH’s P/B Ratio of 2.47 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
MRNA
1.08
Biotechnology Industry
- Max
- 17.92
- Q3
- 10.38
- Median
- 4.78
- Q1
- 2.85
- Min
- 0.78
MRNA’s P/B Ratio of 1.08 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | MOH | MRNA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 8.01 | -- |
| Price-to-Sales Ratio (TTM) | 0.16 | 4.30 |
| Price-to-Book Ratio (MRQ) | 2.47 | 1.08 |
| Price-to-Free Cash Flow Ratio (TTM) | 7.03 | 31.69 |